Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by cactuseskimoon Apr 05, 2021 8:23am
84 Views
Post# 32936187

RE:RE:The future

RE:RE:The future

That is indeed encouraging. I would guess that's all colon/breast sentry revenues which they finally seem to have found a little traction for with the new contacts they've made through Covid. The one encouraging part of this whole clinic purchase is that SZLS has probably pretty much guaranteed themselves annual revenues of 5-10 million moving forward. This is important as Covid testing peters out at some point, and their pretty abysmal track record for cancer related revenue before this point. Again, not the potential tens of millions some might have hoped for with the launch of Aristotle, but it does provide some security and a solid starting point from which to grow and move forward.


JHendrix wrote: According to Q4 report SZLS did almost $500k in cancer tests. Rest of revenue was COVID tests. 

 

<< Previous
Bullboard Posts
Next >>